fda approved indications for semaglutide Advancements in approvals pediatric obesity treatment Navigating the New Frontier: FDA's

Retatrutide has exploded in popularity since Eli Lilly published Phase 2 trial data showing up to 24.2% body weight reduction over 48 weeks

15 The SUSTAIN-FORTE study evaluated weekly semaglutide 2.0 mg versus weekly semaglutide 1 mg in 961 patients with T2D taking metformin with or without a sulfonylurea

1 The results demonstrated that after 68 weeks, patients adhering to cagrilintide/semaglutide treatment experienced a 15.7% weight loss, significantly higher than the 3.1% loss observed with placebo

2024;31(8):1277-1285.[DOI] 61

GLP-1 stands for glucagon-like peptide-1, which is a hormone naturally produced in your gut

Sin embargo, la decisin debe ser mdica y no como automedicacin